801 related articles for article (PubMed ID: 22793066)
21. Efficacy and safety of basiliximab with a tacrolimus-based regimen in liver transplant recipients.
Marino IR; Doria C; Scott VL; Foglieni CS; Lauro A; Piazza T; Cintorino D; Gruttadauria S
Transplantation; 2004 Sep; 78(6):886-91. PubMed ID: 15385809
[TBL] [Abstract][Full Text] [Related]
22. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.
Lin M; Ming A; Zhao M
Clin Transplant; 2006; 20(3):325-9. PubMed ID: 16824149
[TBL] [Abstract][Full Text] [Related]
23. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
Montini G; Murer L; Ghio L; Pietrobon B; Ginevri F; Ferraresso M; Cardillo M; Scalamogna M; Perfumo F; Edefonti A; Zanon GF; Zacchello G
Transpl Int; 2005 Jan; 18(1):36-42. PubMed ID: 15612981
[TBL] [Abstract][Full Text] [Related]
24. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection.
Deeks ED; Keating GM
Drugs; 2009 Jul; 69(11):1483-512. PubMed ID: 19634926
[TBL] [Abstract][Full Text] [Related]
25. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function.
Knight RJ; Kerman RH; Schoenberg L; Podder H; Van Buren CT; Katz S; Kahan BD
Transplantation; 2004 Sep; 78(6):904-10. PubMed ID: 15385812
[TBL] [Abstract][Full Text] [Related]
26. Basiliximab: a review of its use as induction therapy in renal transplantation.
McKeage K; McCormack PL
BioDrugs; 2010 Feb; 24(1):55-76. PubMed ID: 20055533
[TBL] [Abstract][Full Text] [Related]
27. Tacrolimus-Basiliximab versus Cyclosporine-Basiliximab in renal transplantation "de novo": acute rejection and complications.
Martin Garcia D; Martin Gago J; Mendiluce A; Gordillo R; Bustamente J
Transplant Proc; 2003 Aug; 35(5):1694-6. PubMed ID: 12962761
[TBL] [Abstract][Full Text] [Related]
28. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients.
Calmus Y; Scheele JR; Gonzalez-Pinto I; Jaurrieta EJ; Klar E; Pageaux GP; Scudamore CH; Cuervas-Mons V; Metselaar HJ; Prestele H; Girault D
Liver Transpl; 2002 Feb; 8(2):123-31. PubMed ID: 11862588
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and tolerability of interleukin-2 receptor blockade with basiliximab in pediatric renal transplant recipients.
Vester U; Kranz B; Testa G; Malagò M; Beelen D; Broelsch CE; Hoyer PF
Pediatr Transplant; 2001 Aug; 5(4):297-301. PubMed ID: 11472610
[TBL] [Abstract][Full Text] [Related]
30. Effects of Antithymocyte Globulin, Basiliximab, and Induction-Free Treatment in Living Donor Kidney Transplant Recipients on Tacrolimus-Based Immunosuppression.
Sonmez O; Ozcan SG; Karaca C; Atli Z; Dincer MT; Trabulus S; Seyahi N
Exp Clin Transplant; 2024 Apr; 22(4):270-276. PubMed ID: 38742317
[TBL] [Abstract][Full Text] [Related]
31. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K
Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806
[TBL] [Abstract][Full Text] [Related]
32. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group.
Kahan BD; Rajagopalan PR; Hall M
Transplantation; 1999 Jan; 67(2):276-84. PubMed ID: 10075594
[TBL] [Abstract][Full Text] [Related]
33. Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
Tedesco-Silva H; Felipe C; Ferreira A; Cristelli M; Oliveira N; Sandes-Freitas T; Aguiar W; Campos E; Gerbase-DeLima M; Franco M; Medina-Pestana J
Am J Transplant; 2015 Oct; 15(10):2655-64. PubMed ID: 25988935
[TBL] [Abstract][Full Text] [Related]
34. Basiliximab induction in adult liver transplant recipients with 93% rejection-free patient and graft survival at 24 months.
Ramirez CB; Doria C; di Francesco F; Iaria M; Kang Y; Marino IR
Transplant Proc; 2006 Dec; 38(10):3633-5. PubMed ID: 17175352
[TBL] [Abstract][Full Text] [Related]
35. Quadruple immunosuppression with basiliximab, tacrolimus, mycophenolate mofetil and prednisone is safe and effective for renal transplantation.
Miura M; Harada H; Fukuzawa N; Iwami D; Taniguchi A; Seki T; Togashi M; Ogawa Y; Satoh H; Hirano T
Clin Transplant; 2005; 19 Suppl 14():54-8. PubMed ID: 15955170
[TBL] [Abstract][Full Text] [Related]
36. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
[TBL] [Abstract][Full Text] [Related]
37. Correlation between pharmacological efficacy of cyclosporine A and tacrolimus, evaluated by lymphocyte immunosuppressant-sensitivity test (LIST) with MTT assay procedure in renal transplant recipients.
Sugiyama K; Arakawa K; Satoh H; Saito K; Takahashi K; Saito N; Hirano T
J Immunoassay Immunochem; 2006; 27(2):195-205. PubMed ID: 16711256
[TBL] [Abstract][Full Text] [Related]
38. Low rate of acute rejection and cytomegalovirus infection in kidney transplant recipients with basiliximab.
Folkmane I; Bicans J; Amerika D; Chapenko S; Murovska M; Rosentals R
Transplant Proc; 2001; 33(7-8):3209-10. PubMed ID: 11750377
[No Abstract] [Full Text] [Related]
39. Comparative study of clinical outcome in kidney transplantation between early steroid withdrawal protocol using basiliximab, calcineurin inhibitor, and mycophenolate mofetil and triple regimen consisting of calcineurin inhibitor, mycophenolate mofetil, and steroid.
Teraoka S; Sato S; Sekijima M; Iwado K; Urashima Y; Kudo S; Kai K; Koyama I; Tojinbara T; Nakajima I; Fuchinoue S
Transplant Proc; 2005 Mar; 37(2):791-4. PubMed ID: 15848533
[TBL] [Abstract][Full Text] [Related]
40. Immunosuppressive Therapy for Elderly Kidney Transplant Recipients.
Iwamoto H; Nakamura Y; Konno O; Tomita K; Ueno T; Yokoyama T; Kihara Y; Kawachi S
Transplant Proc; 2016 Apr; 48(3):799-801. PubMed ID: 27234739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
